Edmund Dunn's most recent trade in Monte Rosa Therapeutics Inc was a trade of 139 Common Stock done at an average price of $18.0 . Disclosure was reported to the exchange on March 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 17.96 per share. | 04 Mar 2026 | 139 | 22,554 | - | 18.0 | 2,496 | Common Stock |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 18.10 per share. | 27 Feb 2026 | 25,164 | 22,693 | - | 18.1 | 455,506 | Common Stock |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.41 per share. | 27 Feb 2026 | 25,164 | 47,857 | - | 13.4 | 337,449 | Common Stock |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2026 | 25,164 | 536 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 27 Feb 2026 | 536 | 22,693 | - | 17.5 | 9,380 | Common Stock |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.41 per share. | 27 Feb 2026 | 536 | 23,229 | - | 13.4 | 7,188 | Common Stock |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2026 | 536 | 0 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 15.17 per share. | 05 Jan 2026 | 1,039 | 22,693 | - | 15.2 | 15,762 | Common Stock |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 4.45 per share. | 03 Jun 2025 | 2,062 | 23,732 | - | 4.4 | 9,174 | Common Stock |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,400 | 53,400 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 11,850 | 25,794 | - | - | Common Stock | |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 3.83 per share. | 05 Jul 2024 | 1,610 | 13,944 | - | 3.8 | 6,166 | Common Stock |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 4.04 per share. | 03 Jun 2024 | 1,207 | 15,554 | - | 4.0 | 4,876 | Common Stock |
| Monte Rosa Therapeutics Inc | Dunn Edmund | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |